Efficacy and Safety of Transcutaneous Posterior Tibial Nerve Stimulation on Fecal Continence in Patients Undergoing Surgery for Rectal Neoplasia
Randomized Clinical Trial Assessing the Efficacy and Safety of Transcutaneous Posterior Tibial Nerve Stimulation on Fecal Continence in Patients Undergoing Surgery for Rectal Neoplasia
Rectal neoplasia is one of the most prevalent cancers in Spain, and the treatment of choice is total mesorectal excision (TME), as it has demonstrated significant oncological improvements. However, mesorectal excision is not without complications, and patients often experience altered bowel function in the form of low anterior resection syndrome (LARS), as well as erectile dysfunction. However, few studies evaluate faecal incontinence, as most focus on oncological outcomes.
The aim of our study is to evaluate the efficacy and safety of posterior tibial nerve stimulation on fecal incontinence, sexual dysfunction, and quality of life in patients who underwent to rectal surgery for rectal neoplasia.
It will be conducted a randomized clinical trial (1:1) with two arms: half of the patients will receive posterior tibial nerve stimulation, while the other half will undergo stimulation with subtherapeutic doses. Faecal incontinence will be assessed using the LARS and Wexner questionnaires, and quality of life and sexual function will be assessed using the Fecal Incontinence Quality of Life Scale (FIQLS) and the Colorectal Cancer Quality of Life Questionnaire (QLQ-CR38), at one month, six months and one year after surgery.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Meritxell Font
- Número de telefone: +34 676131774
- E-mail: meritxell.fontprat@gmail.com
Locais de estudo
-
-
Barcelona
-
Manresa, Barcelona, Espanha, 08243
- Recrutamento
- Althaia Xarxa Assistencial Universitària de Manresa
-
Contato:
- Anna Arnau, PhD
- Número de telefone: 3414 +34 93 875 93 00
- E-mail: aarnau@althaia.cat
-
Investigador principal:
- Meritxell Font Prat, MD
-
Manresa, Barcelona, Espanha, 08243
- Recrutamento
- Xarxa Assistencial Universitària de Manresa, Althaia
-
Contato:
- Meritxell Font, Medical doctor
- Número de telefone: +34 676131774
- E-mail: meritxell.fontprat@gmail.com
-
Investigador principal:
- Ignasi Puig, Medical doctor
-
Subinvestigador:
- Meritxell Font, Medical doctor
-
Subinvestigador:
- Sheila Serra, Medical doctor
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Adult patients diagnosed with rectal neoplasia and who have undergone a high anterior rectal resection regardless of the surgical approach (open, laparoscopic, laparoscopic+TaTME or robotic+TaTME).
Exclusion Criteria:
- Patients not operated or within active surveillance strategy programs (watch & wait)
- Patients with ostomy
Patients with contraindications to the use of the neurostimulator:
- Pacemaker / Defibrillator / Other electronic devices
- History of heart problems
- Propensity to excessive bleeding (coagulopathies)
- Damage to the nervous system (epilepsy)
- Current pregnancy
- Infections or skin lesions
- Severe vascular disorders
- Active neoplasms.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Intervention group
Posterior tibial nerve stimulation with Beurer EM-49 digital neuroestimulator at complete doses
|
In the intervention group, Beurer EM-49 digital neurostimulator will be used, with CE marking, and a dose of 20 Hertz (Hz) - 200 microseconds (μs) will be applied. As the control group and the intervention group, the pelvic floor rehabilitator will program the neurostimulator for each case and then they will be trained on how to perform the neurostimulation. The first session will be carried out with the rehabilitator to learn how it works and resolve doubts about its use, and later the sessions will be carried out at home. In both groups, a program for carrying out sessions will be indicated according to the following scheme:
|
|
Comparador Falso: Control group
Posterior tibial nerve stimulation with Beurer EM-49 digital neuroestimulator at subtherapeutic doses
|
In the intervention group, Beurer EM-49 digital neurostimulator will be used, with CE marking; and a dose of 80 Hertz (Hz) - 150 microseconds (μs) will be applied. As the control group and the intervention group, the pelvic floor rehabilitator will program the neurostimulator for each case and then they will be trained on how to perform the neurostimulation. In order to apply the therapy, the patient must sit down for the placement of the electrodes. It will be performed on 2 feet at the same time. The first session will be carried out with the rehabilitator to learn how it works and resolve doubts about its use, and later the sessions will be carried out at home. In both groups, a program for carrying out sessions will be indicated according to the following scheme:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Faecal incontinence (FI) - LARS 1st month
Prazo: 1st month post-surgery
|
Assessed by LARS questionnaire Low anterior resection syndrome (LARS): LARS scale consists of 5 questions: gas incontinence (0,4,7 points), liquid incontinence (0,3,3 points), stool frequency (4,2,0,5 points), defecation fractionation (0,9,11 points) and defecatory urgency (0, 11,16 points).
The score range is between 0 and 42 points.
Patients are categorized into three groups: no LARS (0 to 20 points), mild LARS (21 to 29 points) and severe LARS (30 to 42 points).
|
1st month post-surgery
|
|
Faecal incontinence (FI) - LARS 6th month
Prazo: 6th month post-surgery
|
Assessed by LARS questionnaire Low anterior resection syndrome (LARS): LARS scale consists of 5 questions: gas incontinence (0,4,7 points), liquid incontinence (0,3,3 points), stool frequency (4,2,0,5 points), defecation fractionation (0,9,11 points) and defecatory urgency (0, 11,16 points).
The score range is between 0 and 42 points.
Patients are categorized into three groups: no LARS (0 to 20 points), mild LARS (21 to 29 points) and severe LARS (30 to 42 points).
|
6th month post-surgery
|
|
Faecal incontinence (FI) - LARS 12th month
Prazo: 12th month post-surgery
|
Assessed by LARS questionnaire Low anterior resection syndrome (LARS): LARS scale consists of 5 questions: gas incontinence (0,4,7 points), liquid incontinence (0,3,3 points), stool frequency (4,2,0,5 points), defecation fractionation (0,9,11 points) and defecatory urgency (0, 11,16 points).
The score range is between 0 and 42 points.
Patients are categorized into three groups: no LARS (0 to 20 points), mild LARS (21 to 29 points) and severe LARS (30 to 42 points).
|
12th month post-surgery
|
|
Feacal incontinence (FI) - Wexner 1st month
Prazo: 1st month post-surgery
|
Assessed by Wexner questionnaire.
Wexner scale consists of 5 questions (range 0-4): incontinence of solid stools, incontinence of liquid stools, incontinence of gases, use of pads or diapers and alteration of social life.
Depending on the frequency, a score of 0 to 4 is assigned.
The score can range from 0 to 20 points, considering no incontinence as 0 to 2 points, mild incontinence as a result of 3 to 6 points, moderate incontinence as 7 to 11 points and severe incontinence as a result greater than or equal to 12 points.
|
1st month post-surgery
|
|
Faecal incontinence (FI) - Wexner 6th month
Prazo: 6th month post-surgery
|
Assessed by Wexner questionnaire.
Wexner scale consists of 5 questions (range 0-4): incontinence of solid stools, incontinence of liquid stools, incontinence of gases, use of pads or diapers and alteration of social life.
Depending on the frequency, a score of 0 to 4 is assigned.
The score can range from 0 to 20 points, considering no incontinence as 0 to 2 points, mild incontinence as a result of 3 to 6 points, moderate incontinence as 7 to 11 points and severe incontinence as a result greater than or equal to 12 points.
|
6th month post-surgery
|
|
Faecal incontinece (FI) - Wexner 12th month
Prazo: 12th month post-surgery
|
Assessed by Wexner questionnaire.
Wexner scale consists of 5 questions (range 0-4): incontinence of solid stools, incontinence of liquid stools, incontinence of gases, use of pads or diapers and alteration of social life.
Depending on the frequency, a score of 0 to 4 is assigned.
The score can range from 0 to 20 points, considering no incontinence as 0 to 2 points, mild incontinence as a result of 3 to 6 points, moderate incontinence as 7 to 11 points and severe incontinence as a result greater than or equal to 12 points.
|
12th month post-surgery
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Sexual impairment 1st month
Prazo: 1st month post-surgery
|
Assessed by QLQ-CR38 questionnaire (question 17-18 for both sexes, 20-21 for men and 22-23 for women). Each question can be answered from 1 to 4 points. And then is it calculated in the sexual impairment analysis (symptoms area) |
1st month post-surgery
|
|
Sexual impairment - 6th month
Prazo: 6th month post-surgery
|
Assessed by QLQ-CR38 questionnaire (question 17-18 for both sexes, 20-21 for men and 22-23 for women).
Each question can be answered from 1 to 4 points.
And then is it calculated in the sexual impairment analysis (symptoms area)
|
6th month post-surgery
|
|
Sexual impairment - 12th month
Prazo: 12th month post-surgery
|
Assessed by QLQ-CR38 questionnaire (question 17-18 for both sexes, 20-21 for men and 22-23 for women).
Each question can be answered from 1 to 4 points.
And then is it calculated in the sexual impairment analysis (symptoms area)
|
12th month post-surgery
|
|
Quality of life (QoL) - FIQLS 1st month
Prazo: 1st month post-surgery
|
Assessed by: -Fecal Incontinence Quality of Life Scale(FIQLS):composed of 29 items that evaluate 4 health dimensions:lifestyle(10 items),behavior(9 items),depression/self-esteem(7 items) and shame(3 items).Each item has a range from 1 to 5,with 1 being the minimum value for the quality of life state. |
1st month post-surgery
|
|
Quality of life (QoL) - FIQLS 6th month
Prazo: 6th month post-surgery
|
Assessed by: -Fecal Incontinence Quality of Life Scale(FIQLS):composed of 29 items that evaluate 4 health dimensions:lifestyle(10 items),behavior(9 items),depression/self-esteem(7 items) and shame(3 items).Each item has a range from 1 to 5,with 1 being the minimum value for the quality of life state |
6th month post-surgery
|
|
Quality of life (QoL) - FIQLS 12th month
Prazo: 12th month post-surgery
|
Assessed by: -Fecal Incontinence Quality of Life Scale(FIQLS):composed of 29 items that evaluate 4 health dimensions:lifestyle(10 items),behavior(9 items),depression/self-esteem(7 items) and shame(3 items).Each item has a range from 1 to 5,with 1 being the minimum value for the quality of life state |
12th month post-surgery
|
|
Quality of life (QoL) - QLQ-CR 38 1st month
Prazo: 1st month
|
Assessed by: -Colorectal Cancer Quality of Life Questionnaire(QLQ-CR38):organized into 2 areas: 1.Functioning area,which includes the body image and sexual functioning scales and the items on enjoying sex and worrying about the future.2.Symptom area with scales for problems with urination,gastrointestinal symptoms,chemotherapy side effects,problems with defecation,problems with the stoma,sexual problems in men and women,and the weight loss item. All scores ranged 1 to 4, and then are lineal transformation is done (0 to 100). In the functioning area,a higher score indicates a better quality of life,while in the symptom area, a higher score indicates a worse quality |
1st month
|
|
Quality of life (QoL) - QLQ-CR38 6th month
Prazo: 6th month post-surgery
|
Assessed by: -Colorectal Cancer Quality of Life Questionnaire(QLQ-CR38):organized into 2 areas: 1.Functioning area,which includes the body image and sexual functioning scales and the items on enjoying sex and worrying about the future.2.Symptom area with scales for problems with urination,gastrointestinal symptoms,chemotherapy side effects,problems with defecation,problems with the stoma,sexual problems in men and women,and the weight loss item. All scores ranged 1 to 4, and then are lineal transformation is done (0 to 100). In the functioning area,a higher score indicates a better quality of life,while in the symptom area, a higher score indicates a worse quality |
6th month post-surgery
|
|
Quality of life (QoL) - QLQ-CR38 12th month
Prazo: 12th month post-surgery
|
Assessed by: -Colorectal Cancer Quality of Life Questionnaire(QLQ-CR38):organized into 2 areas: 1.Functioning area,which includes the body image and sexual functioning scales and the items on enjoying sex and worrying about the future.2.Symptom area with scales for problems with urination,gastrointestinal symptoms,chemotherapy side effects,problems with defecation,problems with the stoma,sexual problems in men and women,and the weight loss item. All scores ranged 1 to 4, and then are lineal transformation is done (0 to 100). In the functioning area,a higher score indicates a better quality of life,while in the symptom area, a higher score indicates a worse quality |
12th month post-surgery
|
|
Patient global impression of improvement (PGI-I)
Prazo: 1 year
|
Assessed by PGI-I questionnaire. The Patient Global Improvement Visual Analogue Scale (PGI-I) will be used to allow patients to comparatively assess their degree of global improvement after undergoing posterior tibial nerve stimulation therapy. The scale in question has only one question that asks the patient to classify the degree of symptom relief obtained with the treatment according to the 7-point Likert scale. The higher the score, the better the perception of quality of life. |
1 year
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Patient's characteristics
Prazo: At the enrollment
|
Age at diagnosis (years), sex (man/woman), height (m), weight (kg), BMI (kg/m2), prior anorectal disease (yes and not, if yes should specify)
|
At the enrollment
|
|
Concomitant medication for stool
Prazo: At the enrollment
|
methylcellulose, loperamide, ... (yes or no, if yes should specify)
|
At the enrollment
|
|
Tumor characteristics
Prazo: At the enrollment
|
Date of diagnosis (exact day), clinical TNM stage (TNM), tumour height from the anal verge by colonoscopy (cm) and proctoscopy (cm) magnetic resonance imaging findings (TNM, cm to anal verge), neadjuvant treatment (yes or no, which type), CEA values (ng/mL), neutrophil and lymphocyte values pre and post-chemotherapy (absolut value x10e9)
|
At the enrollment
|
|
Surgical details
Prazo: At the enrollment
|
Date of surgery, surgical approach (laparoscopic (LAP), robotic (ROB), LAP + transanal (TaTME), ROB + TaTME), transanal extraction of the specimen (yes or no), intraoperative complications (specify), type of anastomosis (mechanic, manual), height of anastomosis (cm), protective ileostomy (yes or no)
|
At the enrollment
|
|
Follow-up
Prazo: From the surgical day (day 1) to the end of the study (day 360)
|
Days of hospital stay (days), days until intake (days), postoperative complications (yes or no, if yes specify and complete Clavien-Dindo clasification), treatment of postoperative complication (need of new surgery, yes or no, if yes specify surgical procedure), readmission (yes or no, specify why)
|
From the surgical day (day 1) to the end of the study (day 360)
|
|
Esphinteric funcionality
Prazo: At 1st month and 12th month from day 1 (surgery day)
|
Rectal examination with basal tone and transperineal ultrasound (normal, insufficient expulsive maneuver, sphincter defect, anism, rectal hypersensitivity, rectal hyposensitivity, not performed), Oxford classification of esphinteric muscular strenght (0 to 5, being 5 good function).
|
At 1st month and 12th month from day 1 (surgery day)
|
|
Compliance diary
Prazo: 1 year
|
Registration of the sessions done and observations
|
1 year
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Links úteis
- Sociedad Española de Oncología Médica (SEOM). Las cifras del càncer en España. 2024.
- El cáncer en España, datos y estadísticas. Epdata.
- Ma B, Gao P, Song Y, Zhang C, Zhang C, Wang L, et al. Transanal total mesorectal excision (taTME) for rectal cancer: A systematic review and meta-analysis of oncological and perioperative outcomes compared with laparoscopic total mesorectal excision.
- Muratore A, Mellano A, Marsanic P, De Simone M. Transanal total mesorectal excision (taTME) for cancer located in the lower rectum: Short- and mid-term results. European Journal of Surgical Oncology. 2015; 41(4): 478-83.
- Color II Study Group, Buunen M, Bonjer HJ, Hop WCJ, Haglind E, Kurlberg G, et al. COLOR II. A randomized clinical trial comparing laparoscopic and open surgery for rectal cancer. Danish Medical Bulletin. 2009; 56(2): 89-91.
- Van der Pas MH, Haglind E, Cuesta MA, Fürst A, Lacy AM, Hop WC, et al. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. Lancet Oncology. 2013; 14(3): 210-8.
- Sanchon L., Bardají M., Labró M., Curto J., Soto C., Puig A., et al. Oncological monitoring after transanal total mesorectal excision (TaTME) for rectal neoplàsia. Techniques in Coloproctology. 2023: 27(9):739-746.
- Grass J. K., Chen C-C., Melling N., Lingala B., Kemper M., Scognamiglio P., et al. Robotic rectal resection preserves anorectal function: systematic review and meta-analysis. Int J Med Robot. 2021; 17(6):e2329.
- Emmertsen KJ, Laurberg S. Low anterior resection syndrome score: development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer. Annals of Surgery. 2012; 255(5): 922-8.
- Sörensson M, Asplund D, Matthiessen P, Rosenberg J, Hallgren T, Rosander C, et al. Self-reported sexual dysfunction in patients with rectal cancer. Color Disease. 2020; 22(5): 500-12.
- Carrillo A, Enríquez-Navascués JM, Rodríguez A, Placer C, Múgica JA, Saralegui Y, et al. Incidencia y caracterización del síndrome de resección anterior de recto mediante la utilización de la escala LARS (low anterior resection score). Cirugía Españo
- Kauff DW, Roth YDS, Bettzieche RS, Kneist W. Fecal incontinence after total mesorectal excision for rectal cancer-impact of potential risk factors and pelvic intraoperative neuromonitoring. World Journal of Surgical Oncology. 2020; 18(1).
- Zhang, L., Hu C., Zhao J., Wu C., Zhang Z., Li R., et al. The effect of robotic surgery on low anterior resection syndrome in patients with lower rectal cancer: a propensity score-matched analysis. Surgical Endoscopy 2024; 38(4): 1912-1921.
- Vidal C., Romero G., Jané C., Vidal L., Arnau A., Rosal A., et al. Intervención no farmacològica para mejorar la calidad de vida de los pacientes intervenidos de resección anterior de recto. Revista Sociedad Española de Enfermería en Estomaterapia. 2
- Rosen H., Sebesta C.G., Sebesta C. Cancers (Basel). 2023; 15(3): 778
- Nguyen TH, Chokshi R V. Low Anterior Resection Syndrome. Current Gastroenterology Reports. Springer; 2020; 22(10): 48.
- Ciriza de los Ríos C, Ruiz de León A, García Durán F, Tomás Moros E, Carneros Martín JA, Muñoz Yagüe T, et al. Calidad de vida en pacientes con incontinencia fecal y su relación con la gravedad de la misma.Gastroenterología Hepatología. 2010; 33(9):621-8
- Efisioterapia. T.E.N.S. Estimulación nerviosa transcutánea. eFisioterapia.net. 2007.
- Medicina del Dolor. Hospital VITHAS Valencia.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Genitais
- Complicações pós-operatórias
- Processos Patológicos
- Neoplasias por local
- Neoplasias
- Doenças Genitais, Masculino
- Doenças Urogenitais Masculinas
- Doenças Intestinais
- Neoplasias gastrointestinais
- Neoplasias do Aparelho Digestivo
- Doenças do aparelho digestivo
- Doenças Gastrointestinais
- Neoplasias Colorretais
- Neoplasias Intestinais
- Doenças retais
- Doenças do cólon
- Disfunção Sexual Fisiológica
- Condições Patológicas, Sinais e Sintomas
- Síndrome de Ressecção Anterior Baixa
- Disfunção Ejaculatória
- Neoplasias retais
- Incontinência fecal
- Técnicas de investigação
- Design de pesquisa epidemiológica
- Métodos epidemiológicos
- Design de pesquisa
- Métodos
- Grupos de controle
Outros números de identificação do estudo
- CEIm 25/080
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .